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ESTUDIO ALEATORIZADO, DOBLE-CIEGO 
Y CONTROLADO POR PLACEBO DEL EFECTO 
DE UN SIMBIÓTICO SOBRE EL TRÁNSITO 
INTESTINAL EN MUJERES ADULTAS SANAS
Resumen
Objetivo: Evaluar el tiempo de tránsito intestinal (TTI)
antes y después de consumir yogur con Bifidobacterium
BB12, Lactobacillus casei CRL 431 y fibra (simbiótico).
Métodos: Estudio prospectivo, cruzado, aleatorizado y
doble-ciego con 4 fases: preparación (tiempo 0); interven-
ción (yogur o simbiótico; tiempo 1 y tiempo 3); sin inter-
vención (tiempo 2). Evaluamos la frecuencia de defeca-
ción y el consumo de fibra. El TTI se estimo con rojo
carmín. 
Resultados: La edad promedio fue 40,7 años (n = 102
mujeres sanas; 83 completaron el estudio). En mujeres
con TTI inicial (TTII) ≥ 48 h que consumieron el simbió-
tico, el TTII y el TTI final (TTIF) fue 86,9 ± 38,5 h y 51,2 ±
29,8 h (-40,9%), respectivamente, comparado con el de
mujeres que consumieron el producto control (TTII, 80,8
± 31,7 h; TTIF, 69,5 ± 31,5 h; -13,8%) (p = 0,001). En
mujeres con constipación funcional que consumieron el
producto control, el TTII fue 57,0 ± 30,0 h, valor que
aumentó 2,8 h después de consumir el producto (TTIF,
59,8 ± 30,2 h; + 4,9%). El TTII en mujeres que consumie-
ron el simbiótico fue 69,0 ± 49,6 h, registrándose una dis-
minución de 27,5% 19 h después del consumo (TTIF, 50,0
± 27,5 h; p = 0,023). La normalización de la flora láctica
entérica fue significativamente mayor en mujeres que
consumieron el simbiótico al inicio (p < 0,1).
Conclusión: El TTI disminuyó significativamente des-
pués de consumir el simbiótico. Dicho efecto beneficioso
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Abstract
Objective: To evaluate oro-cecal intestinal transit time
(ITT) before and after administration of a dairy product
containing Bifidobacterium BB12, Lactobacillus casei
CRL 431 and fiber in healthy women.
Methods: A prospective, randomised, double-blind and
cross-over study with a 4-phase design (run-in: time 0
[T0], two intervention periods: time 1 [T1] and time 3
[T3] and a wash-out: time 2, [T2]) was performed. Parti-
cipants were asked about bowel movement and fiber
consumption. ITT was assessed by the carmine red dye
method. 
Results: Mean age was 40.7 years (n = 102 healthy
women; 83 completed the study). In women with initial
ITT (IITT) ≥ 48 h consuming the synbiotic product, mean
IITT and final ITT (FITT) was 86.9 ± 38.5 h and 51.2 ±
29.8 h (-40.9%), as compared to women consuming the
control yoghurt (IITT, 80.8 ± 31.7 h; FITT, 69.5 ± 31.5 h; 
-13.8%) (p = 0.001). IITT in women with functional cons-
tipation consuming the control yoghurt was 57.0 ± 30.0 h;
such figure increased 2.8 h after yoghurt consumption
(FITT, 59.8 ± 3 0.2 h; +4.9%). Conversely, IITT in women
who received the synbiotic yoghurt was 69.0 ± 49.6 h, with
a -27.5% decrease 19 h later (FITT, 50.0 ± 27.5 h; p =
0.023). Enteric lactic flora stabilization was significantly
higher in women who initially consumed the synbiotic
product (p < 0.1).
Conclusion: ITT decreased significantly after consump-
tion of the synbiotic product. Such beneficial effect was
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Introduction
Bowel disorders vary from person to person and are
influenced by cultural factors.1 The most common func-
tional gastrointestinal disorders are irritable bowel syn-
drome, constipation and bloating, and they have a higher
prevalence in women.1 Constipation is classified into 3
main classes: normal-transit, slow-transit, and defeca-
tory disorders, being normal-transit constipation the
most prevalent class (59%).2 Patients with this disorder
only have three bowel movements or fewer in a week;
stool frequency is normal, yet they believe they are con-
stipated. In these patients, constipation is likely to be due
to a perceived difficulty with evacuation or the presence
of hard stools; they may also experience bloating and
abdominal pain or discomfort.3
The presence of pain and slow-transit is favored by
lifestyle habits, particularly low fiber intake, insuffi-
cient water intake and scarce practice of physical acti -
vity.2 Therefore, constipation and bloating can be han-
dled with diet and healthy habits, although dietary fiber
supplements or laxatives can also be used.4 In this con-
text, the use of prebiotics and probiotics in every day
diet has been shown to be effective.5-9
Probiotics are defined as food or drugs containing
live microorganisms, such as Lactobacillus, Bifidobac-
terium and Streptococcus,10 that exert a beneficial
physiological effect on the host.11 Prebiotics are short-
chain carbohydrates resisting digestion by gastric acid
and pancreatic enzymes; to be effective, they must
reach the cecum, where they are fermented by bacteria
and may positively influence intestine function.12
The term synbiotic is used to define products con-
taining both prebiotics and probiotics, in which the pre-
biotic compound selectively favors the probiotic com-
pound. They are functional foods that stimulate the
growth of lactic microflora,13 reason why dairy prod-
ucts are the vehicle of choice for these compounds.14
The positive effect of some prebiotics and probiotics
on different gastrointestinal dysfunctions, such as gas-
trointestinal infection, constipation, lactose intoler-
ance, inflammatory bowel disease, and probably colon
cancer, is supported by evidence in the literature.15,16
In this study, we evaluated oro-cecal intestinal transit
time (ITT) in healthy women before and after administra-
tion of a dairy product containing Bifidobacterium BB12,
Lactobacillus casei CRL 431 and fiber, as compared to
placebo administration. We further determined the effect
of both products on stool consistency and frequency, as
well as symptomatic improvement (bloating and abdom-
inal pain) at the end of the study.
Materials and methods
Design of the study
The study was prospective, randomised, double-blind
and cross-over, and was carried out at IDIP – Instituto de
Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fer-
nando E. Viteri” (La Plata’s Children Hospital, Buenos
Aires, Argentina). It had a 4-phase design, i.e., 4 consecu-
tive periods of 15 days each: preparation or run-in (time
0; T0), and two intervention periods (time 1 and 3; T1 and
T3) separated by a wash-out (time 2; T2). Participants
were randomly assigned to one of two groups according
to the last two digits of their identity card number (odd or
even). Study group 1 received standard yoghurt (T0),
control yoghurt (T1), standard yoghurt (T2), and synbi-
otic yoghurt (T3). Study group 2 was given standard
yoghurt (T0), synbiotic yoghurt (T1), standard yoghurt
(T2), and control yoghurt (T3).
Subjects
A total of 102 healthy adult volunteer women aged
21-60 years and living in the city of La Plata, Province
of Buenos Aires, Argentina, were recruited through
street interviews. Inclusion criteria were women with
slow-transit perception, abdominal pain and ITT > 24 h
and willing to participate in the study. Exclusion crite-
ria were use of medication that could affect intestinal
transit, and/or diagnosis of any disease.
Women were asked to answer a questionnaire about
dietary habits and bowel movement. Those with slow-
transit perception and/or abdominal pain (bloating) or
slow-transit (functional constipation) according to
Rome III criteria17 were invited to participate in the study
and further asked to assess ITT by the carmine red dye
method (see Dye method). Only those volunteers with
ITT > 24 h were included in the study (n = 83). 
Before the study, a semi-quantitative survey about
frequency of consumption was made to assess dietary
fiber intake.
Yoghurt, cultured and/or fermented milk and laxa-
tive consumption was stopped 15 days before and dur-
ing the study period. Participants were then instructed
to go on their habitual diet. 
All subjects gave their informed consent to partici-
pate in the study. The study protocol was approved by
IDIP´s Institutional Research Protocol Review Board.
Dairy products
All products (synbiotic, control and standard yoghurt)
were elaborated two weeks before each phase by San-
Cor CUL Ltd (Sunchales, Argentina) and handed out in
pots containing 125 g of yoghurt with the same appear-
ance and taste.
The synbiotic yoghurt contained 0.625 g of prebi-
otics (inulin and oligofructose), the probiotic Bifi-
dobacterium lactis BB12 (109-1010 colony forming
units [CFU]), the probiotic Lactobacillus casei CRL
431 (1 x 109-6 x 109 CFU), Lactobacillus bulgaricus
(109-1010 CFU), and Streptococcus thermophilus (109-
1010 CFU).
Intestinal transit time and synbiotic
consumption
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The control and the standard yoghurt contained Lac-
tobacillus bulgaricus (109-1010 CFU) and Streptococ-
cus thermophilus (109-1010 CFU), and the same
organoleptic characteristics as those of the synbiotic
product. The only difference between them was in the
color of the label.
Participants collected the corresponding product
weekly throughout the study, and were instructed to
consume 2 yoghurts per day during each phase. 
Dye method
ITT estimations in each study period were done with
carmine red dye, a safe and non-invasive method cur-
rently used.18,19 Women were given1 g carmine red in cap-
sules and had to register date and time of consumption on
a record sheet. They also had to register date and time of
elimination of the dye in stools, as determined by the
change of color to intense orange or red. The procedure
was repeated twice in each study phase, and the mean of
both measurements was used to determine ITT in each
participant. Women were asked not to eat food that could
change the color of their stool, such as beetroot.
Stool analysis
Stool samples were collected at T0 (run in), T1 (syn-
biotic or control period) and T2 (wash-out). T3 was not
considered because samples could be influenced by the
products ingested during the previous periods.
Each stool sample was weighed and resuspended in
0.1% sterile peptone water. Thereafter, adequate dilu-
tions for the corresponding cultures in differential
media were made. Final counts were referred to CFU
per gram of feces (CFU/g). 
The culture media used were BHI agar for total aero-
bic bacteria (aerobic incubation), BHI for total anaero-
bic bacteria (anaerobic incubation), LBS agar (lacto-
bacilli selective agar) for lactobacilli, KF agar for
enterobacteria and streptococcus, Mc Conkey for
enterobacteria, and modified HHD for bifidobacteria.
Statistical analysis
In all cases, repeated measures analysis of variance
was used to determine the effect of the synbiotic pro -
duct. χ2 was used to compare proportions in intestinal
symptom improvement. 
Results
Mean age was 40.7 years; 83 out of the 102 healthy
women completed the study and 19 dropped out (6 due
to initial ITT (IITT) < 24 h, 6 due to causes unrelated to
the study, 5 due to intercurrent disease without digestive
function compromise [influenza, respiratory disease], 1
due to constipation and 1 due to bloating).
Mean IITT and FITT was 68.0 ± 39.8 and 46.4 ± 26.5,
respectively, in women consuming the synbiotic product
(ITT decrease of 16.6 ± 34.4 h; -27.6%). In women con-
suming the control yoghurt, mean IITT and FITT was
62.6 ± 34.3 h and 56.4 ± 30.7 h, respectively (ITT
decrease of 3.68 ± 28.2 h; -6.36%; p = 0.005; fig. 1).
In women with IITT ≥ 48 h and consuming the synbi-
otic product, mean IITT and FIIT was 86.9 ± 38.5 h and
51.2 ± 29.8 h, respectively (-40.9%). In those receiving
the control yoghurt, mean IITT and FITT was 80.8 ±
31.7 h and 69.5 ± 31.5 h (-13.8%; p = 0.001; fig. 2).
Results of the consequences of dairy product con-
sumption in women with functional constipation are
shown in figure 3. At the beginning of the study, 63
women with functional constipation were selected, 35
consumed control yoghurt and 28 the synbiotic prod-
uct. IITT in the former was 57.0 ± 30.0 h; such figure
increased 2.8 h after yoghurt consumption (FITT, 59.8
±3 0.2 h; +4.9%). Conversely, IITT in women who
ingested the synbiotic yoghurt was 69.0 ± 49.6 h, with a
-27.5% decrease 19 h later (FITT, 50.0 ± 27.5 h; p =
0.023; fig. 3).
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Fig. 1.—Changes in intestinal transit time (ITT) after synbiotic
and control yoghurt consumption. (IITT: initial intestinal tran-













Fig. 2.—Changes in intestinal transit time (ITT) after synbiotic
and control yoghurt consumption in women with initial ITT ≥
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Changes in other bowel habits were concerned with
voiding frequency, stool consistency and bloating. Stool
consistency was not significantly different in either
group (synbiotic vs. control). In the case of women who
consumed the synbiotic product, there was a marked
improvement in abdominal bloating as compared with
those consuming the control yoghurt (p = 0.04). Even
though not significant, there was a trend toward
improvement in the frequency of voiding in women who
consumed the synbiotic product (p = 0.07).
Results of the dietary survey indicated that con-
sumption of fiber in the diet or with the dairy product
with prebiotics was 10.7 and 1.25 g/day, respec-
tively.
Changes in stool consistency were within the frame-
work of intestinal flora dynamic balance in both study
groups. Enteric lactic flora stabilization was signifi-
cantly higher in Group 2 (p < 0.1) as compared to
Group 1 (fig. 4). Whereas women in Group 2 had a sig-
nificant decrease in gram-positive cocci and enterobac-
teria from T1 onwards (p < 0.1), no significant differ-
ences were detected in women from Group 1. In Group
1, there were no significant differences in bifid flora
between T0 and T1/T2, whereas in Group 2 such dif-
ferences were significant from T1 and remained until
the end of the study (p < 0.1; fig. 5).
Intestinal transit time and synbiotic
consumption
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Fig. 3.—Changes in intestinal transit time (ITT) after synbiotic
and control yoghurt consumption in women with functional
constipation at the beginning of the study. (IITT: initial intesti-
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Discussion
Our results show the beneficial effect of synbiotic
yoghurt consumption on ITT in healthy adult women,
particularly in women with IITT > 48 h or functional
constipation, who had the highest benefit. 
Previous reports have demonstrated the beneficial
effect of the probiotics used in our study on intestinal
microflora. A significant increase of fecal bifidobacte-
ria has been reported in intestinal microflora of elderly
people after 2-week consumption of BB12-containing
yoghurt.20 Another study on elderly people showed that
BB12 yoghurt consumption improved intestinal
microflora, suggesting that probiotic qualities of this
strain are optimal for adult people.21
On the other hand, our study represents the first
investigation about consumption of Lactobacillus
casei CRL 431 and its effect on people suffering con-
stipation. This strain was tried in adult lactose-intoler-
ant people;22 although it was not the main aim of the
study, in this report the protocol included measurement
of oro-cecal transit time, which showed a statistically
significant decrease.
A review on prebiotics (oligofructose, galacto-
oligosaccharides and lactulose) showed that they are
the most effective products for improving intestinal
microflora, with increased levels of bifidobacteria and
lactobacilli.12
In the study by Marteau and Boutron-Ruault, increased
intestinal peristalsis due to prebiotic consumption was
the result of bacterial growth stimulation and of the
osmotic effect exerted when passing through the
intestinal tract.15
The relationship prebiotic/laxative effect is still a
matter of discussion because research protocols were
not comparable and study samples diverse.12
A review of randomized controlled studies evaluat-
ing the efficacy and safety of probiotics for the treat-
ment of functional constipation in adults determined
that Escherichia coli Nissle 1917, Lactobacillus casei
Shirota and Bifidobacterium lactis DN-173010 were
the most effective strains. All studies agreed on higher
stool frequency and decreased stool consistency; how-
ever, the clinical relevance of such findings is still
under discussion.23
In other reports of constipated women who con-
sumed the probiotic Bifidobacterium lactis DN-
173010, a 3.7-h decrease (-6.7%) in colonic transit time
and an 8-h decrease (-11.3%) in women with IITT of
40 h was observed.8 Although we measured oro-cecal
transit with carmine dye, results showed a marked
decrease in transit time.
Another paper evaluating the effect of a synbiotic
product (Bifidobacterium lactis DN-173010 + inulin) on
evacuatory habits in women with functional constipa-
tion showed a significant increase in weekly stool fre-
quency in women consuming the synbiotic (6.1 ± 2.7
stools/week) as compared to those in the control group
(5.0 ± 2.6 stools/week), together with improved parame-
ters of bowel movement (quality of feces, excessive
straining, pain associated to evacuation).24 Our findings
are similar to those mentioned above, even when the
observational methods used were different.
Synbiotic food is also used in constipated patients
with irritable bowel syndrome. Dughera et al.25 sug-
gest promisory positive effects on clinical manifesta-
tions and intestinal function in treated patients; their
data show improvements in abdominal pain and
bloating as well as increased stool frequency. Similar
results were reported by Colecchia et al.,26 indicating
that the synbiotic product also increased stool fre-
quency and improved symptoms.
Other strains of probiotics have been studied to deter-
mine their effect on stool frequency and intestinal
microflora; the intake of a dairy product containing Bifi-
dobacterium lactis FK120 improved fecal microflora
and promoted bowel movement in young healthy
women27 and healthy volunteers.28
The observed changes in microflora indicate that
consumption of a synbiotic product at the beginning of
the trial (Group 2) caused statistically significant
changes in the microflora (increased bifidobacteria and
decreased enterobacteria) from T1 onwards (p < 0.1),
that remained until the end of the trial.
Some authors correlate symptoms, abdominal pain
and bloating with decreased lactobacilli and bifidobac-
teria in intestinal microflora.29 However, as suggested
by Dughera et al.,25 studies on the use of probiotics to
relieve symptoms are controversial; while some
authors say that the use of lactobacilli is effective for
symptom treatment,30 others state that probiotics are
effective with bifidobacteria and not lactobacilli.31 Fur-
ther studies in comparable population samples are
needed to evaluate such effects.
Conclusion
Our results suggest that the synbiotic product
designed by our group caused a significant decrease in
ITT, and that such beneficial effect was more evident
in women with IITT ≥ 48 h and in those suffering func-
tional constipation. 
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